Mechanism of Action Trial of ColoAd1

Inclusion criteria: Patients must meet all the following criteria to be eligible for participation: * Able and willing to provide written informed consent and to comply with the study protocol * Age ≥ 18 years * Patients with histologically confirmed resectable colon cancer, NSCLC (squamous and non-squamous), bladder cancer (urothelial cell carcinoma) or RCC (renal cell carcinoma), scheduled for resection of primary tumour and with planned resection of draining lymph nodes for colon cancer * Diagnostic colonoscopy performed at the study centre (Cohorts A and B only) or a referral centre (Cohort B only) and a report from this colonoscopy available for the study * Tumour size of 3 cm or more in diameter as estimated during diagnostic colonoscopy for cohorts A and B or by CT-scan for cohorts C, D and E. * At least 2 weeks since the last dose of any intravenous systemic chemotherapy at time of first administration of ColoAd1 * Recovered to Grade 1 from the effects (excluding alopecia) of any prior therapy for their malignancies. * Able to undergo surgery with general anaesthesia * Surgery planned and administration of ColoAd1 feasible within * 15 days of planned surgery (following IT administration or following first dose of IV administration) for cohorts A and B * 10 - 25 days of first ColoAd1 administration for cohorts C, D and E * ECOG Performance Status Score of 0 or 1 * Adequate renal function * Creatinine ≤ 1.5 mg/dL or calculated creatinine clearance using the Cockcroft-Gault formula ≥ 60 mL/min, or measured creatinine clearance ≥60 mL/min, * Absence of clinically significant haematuria on urinalysis: dipstick \< 2+ * Absence of clinically significant proteinuria on urinalysis: dipstick \< 2+. * Adequate hepatic function * serum bilirubin \<1.5 x ULN * AST and ALT ≤ 3 x ULN * Adequate bone marrow function: * ANC ≥ 1.5 x 109/L, * platelets ≥ 100 x 109/L, * haemoglobin ≥ 90 g/L * Adequate coagulation tests: INR ≤ 1.5 x ULN; * For females of childbearing potential (defined as \<2 years after last menstruation or not surgically sterile), a negative pregnancy test must be documented prior to enrolment; * For women who are not postmenopausal (24 months of amenorrhea) or surgically sterile (absence of ovaries and/or uterus): agreement to use two adequate methods of contraception, including at least one method with a failure rate of \< 1% per year (e.g., hormonal implants, combined oral contraceptives, vasectomized partner), during the treatment period and for at least 3 months after the last dose of study drug; * For men: agreement to use a barrier method of contraception during the treatment period and for at least 6 months after the last dose of study drug Exclusion Criteria for all patients: Patients who meet any of the following criteria are not eligible for enrolment: * Rectal tumours; (cohorts A and B); * An obstructive tumour of the intestine (cohorts A and B only) or of the urinary tract (cohort D); * Any condition necessitating surgery in less than 8 days (cohorts A or B) or 10 days (cohorts C, D or E); * Pregnant or lactating (nursing) women; * Known and/or a history or evidence of significant immunodeficiency due to underlying illness (e.g. HIV/AIDS) and/or medication (e.g. systemic corticosteroids at doses higher than dexamethasone 10 mg or equivalent, or other immunosuppressive medications including cyclosporine, azathioprine, interferons, within the past 4 weeks); * Splenectomy * Prior allogeneic or autologous bone marrow or organ transplantation * Active infections requiring antibiotics, physician monitoring, or recurrent fevers \>38.0 degrees centigrade associated with a clinical diagnosis of active infection * Active viral disease, positive serology for HIV, hepatitis B or hepatitis C * Use of the following anti-viral agents: * ribavirin, adefovir, lamivudine or cidofovir within 7 days prior to day 1; * or PEG-IFN (within 14 days prior to day 1); * Administration of an investigational drug within 28 days prior to first dose of ColoAd1 * Major surgery within 4 weeks or radiotherapy within 3 weeks prior to first dose of ColoAd1 * Another primary malignancy within the past 3 years (except for non-melanoma skin cancer or cervical cancer in situ) * Known CNS metastasis * Inflammatory diseases of the bowel (cohorts A and B only) or any inflammatory disease that may require treatment with corticosteroids. * Any condition or illness that, in the opinion of the Investigator or the medical monitor, would compromise patient safety or interfere with the evaluation of the safety of the drug * Known allergy to treatment medication or its excipients * Any other medical or psychological condition that would preclude participation in the study or compromise ability to give informed consent.